NRX Pharmaceuticals, Inc. (NRXP) financial statements (2022 and earlier)

Company profile

Business Address 1201 N. MARKET STREET
WILMINGTON, DE 19801
State of Incorp. DE
Fiscal Year End December 31
SIC 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in thousands)

12/31/2021
12/31/2020
12/31/2019
12/31/2018
12/31/2017
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments27,6050011449
Cash and cash equivalents27,6050011449
Prepaid expense3,5693069  
Other undisclosed current assets1,54052 1987
Total current assets:32,714826930536
Noncurrent Assets
Assets held-in-trust 5,96832,00570,76669,029
Other noncurrent assets15    
Total noncurrent assets:155,96832,00570,76669,029
TOTAL ASSETS:32,7296,05032,07570,79669,566
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities, including:6,06261062255186
Accounts payable3,687    
Accrued liabilities2,375   8
Taxes payable   16 
Other undisclosed accounts payable and accrued liabilities 61062253578
Deferred revenue292  
Debt 1,810   
Derivative instruments and hedges, liabilities 655   
Due to related parties 862   
Business combination, contingent consideration, liability4,582    
Other undisclosed current liabilities987  168
Total current liabilities:11,9233,93762256793
Noncurrent Liabilities
Long-term debt and lease obligation  1,536690 
Long-term debt, excluding current maturities  1,536690 
Liabilities, other than long-term debt  416  
Due to related parties  416  
Total noncurrent liabilities:  1,952690 
Total liabilities:11,9233,9372,5741,25793
Temporary equity, carrying amount  24,50064,53964,473
Stockholders' equity
Stockholders' equity attributable to parent20,8062,1145,0005,0005,000
Common stock593333
Additional paid in capital203,9902,8314,6285,0365,102
Retained earnings (accumulated deficit)(183,243)(720)369(39)(105)
Total stockholders' equity:20,8062,1145,0005,0005,000
TOTAL LIABILITIES AND EQUITY:32,7296,05032,07570,79669,566

Income statement (P&L) ($ in thousands)

12/31/2021
12/31/2020
12/31/2019
12/31/2018
12/31/2017
Operating expenses(115,796)(907)(713)(1,007) 
Operating loss:(115,796)(907)(713)(1,007) 
Nonoperating income (expense)22,733(164) 1,089 
Interest and debt expense121352   
Income (loss) from continuing operations before equity method investments, income taxes:(92,942)(720)(713)82 
Other undisclosed income (loss) from continuing operations before income taxes(121)(352)1,206  
Income (loss) from continuing operations before income taxes:(93,063)(1,072)49382 
Income tax expense (18)(84)(16) 
Net income (loss) attributable to parent:(93,063)(1,090)40866 
Other undisclosed net loss available to common stockholders, basic(255,822) (704)(815) 
Net loss available to common stockholders, diluted:(348,885)(1,090)(295)(749) 

Comprehensive Income ($ in thousands)

12/31/2021
12/31/2020
12/31/2019
12/31/2018
12/31/2017
Net income (loss):(93,063)(1,090)40866 
Comprehensive income (loss), net of tax, attributable to parent:(93,063)(1,090)40866 

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: